• Explore /
  • Poster
  • / A phase I trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.

A phase I trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with solid tumors and lymphomas.

Abstract Poster

Authors

null

Robert S. Meehan

Early Clinical Trials Development Program, DCTD, National Cancer Institute at the National Institutes of Health, Bethesda, MD

Robert S. Meehan , Geraldine Helen O'Sullivan Coyne , Shivaani Kummar , Jerry M. Collins , Larry Anderson , Jennifer Zlott , Lamin Juwara , Naoko Takebe , Richard Piekarz , Howard Streicher , Elad Sharon , Barbara A. Conley , Larry Rubinstein , Deborah Wilsker , Angie B Dull , Katherine V. Ferry-Galow , Robert J. Kinders , Ralph E. Parchment , James H. Doroshow , Alice P. Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT01851369

Citation

J Clin Oncol 35, 2017 (suppl; abstr 2518)

DOI

10.1200/JCO.2017.35.15_suppl.2518

Abstract #

2518

Poster Bd #

10

Abstract Disclosures

Similar Posters

First Author: Sarah Shin

First Author: Vincent Chung

First Author: Todd Michael Bauer

Poster

2023 ASCO Annual Meeting

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.

A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.

First Author: Jordi Rodon Ahnert